<SEC-DOCUMENT>0000320017-17-000037.txt : 20170509
<SEC-HEADER>0000320017-17-000037.hdr.sgml : 20170509
<ACCEPTANCE-DATETIME>20170509165201
ACCESSION NUMBER:		0000320017-17-000037
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20170509
DATE AS OF CHANGE:		20170509
EFFECTIVENESS DATE:		20170509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Caladrius Biosciences, Inc.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		17827244

	BUSINESS ADDRESS:	
		STREET 1:		106 ALLEN ROAD
		STREET 2:		FOURTH FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-842-0100

	MAIL ADDRESS:	
		STREET 1:		106 ALLEN ROAD
		STREET 2:		FOURTH FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHASE III MEDICAL INC/DE
		DATE OF NAME CHANGE:	20030819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNICHE GROUP INC /DE
		DATE OF NAME CHANGE:	19951117
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>defa14a050917.htm
<DESCRIPTION>DEFA14A 05.09.17
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s94a9da897beb422d915261cba40320d0"></a></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:15pt;"><font style="font-family:inherit;font-size:15pt;font-weight:bold;">UNITED STATES </font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:15pt;"><font style="font-family:inherit;font-size:15pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, DC&#160;20549</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">______________</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:15pt;"><font style="font-family:inherit;font-size:15pt;font-weight:bold;">SCHEDULE&#160;14A</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Proxy Statement&#160;Pursuant to Section&#160;14(a) of the </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Exchange Act of&#160;1934 </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">___________________</font></div><div style="line-height:120%;padding-bottom:5px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed by the Registrant &#9746; Filed by a party other than the Registrant &#9744;</font></div><div style="line-height:120%;padding-bottom:5px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box:</font></div><div style="line-height:120%;padding-bottom:5px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;&#160;&#160;&#160;&#160;Preliminary Proxy Statement</font></div><div style="line-height:120%;padding-bottom:5px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Confidential, for Use of the Commission Only (as permitted by Rule&#160;14a-6(e)(2))</font></div><div style="line-height:120%;padding-bottom:5px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;&#160;&#160;&#160;&#160;Definitive Proxy Statement</font></div><div style="line-height:120%;padding-bottom:5px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9746;&#160;&#160;&#160;&#160;Definitive Additional Materials</font></div><div style="line-height:120%;padding-bottom:5px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;&#160;&#160;&#160;&#160;Soliciting Material Under &#167; 240.14a-12</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">CALADRIUS BIOSCIENCES, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Name of Registrant as Specified In Its Charter)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</font></div><div style="line-height:120%;padding-bottom:5px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of Filing Fee (Check the appropriate box):</font></div><div style="line-height:120%;padding-bottom:5px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9746;&#160;&#160;&#160;&#160;No fee required.</font></div><div style="line-height:120%;padding-bottom:5px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;&#160;&#160;&#160;&#160;Fee computed on table below per Exchange Act Rules&#160;14a-6(i)(1) and&#160;0-11.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title of each class of securities to which transaction applies:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate number of securities to which transaction applies:</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule&#160;0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proposed maximum aggregate value of transaction:  </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total fee paid: </font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:5px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#9744;&#160;&#160;&#160;&#160;Fee paid previously with preliminary materials.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#9744;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check box if any part of the fee is offset as provided by Exchange Act Rule&#160;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.  Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amount previously paid:  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form, Schedule or Registration Statement&#160;No.:  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filing party:  </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(9)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date Filed:</font></div></td></tr></table><div><br></div><hr style="page-break-after:always"><div><a name="scf02797ea82a4890ac43db9903d16fe4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 9, 2017, Caladrius Biosciences, Inc. (&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Caladrius</font><font style="font-family:inherit;font-size:10pt;">&#8221;) made the following communication in connection with Caladrius' upcoming shareholder meeting encouraging stockholders to vote their shares in favor of  the proposed transactions under that certain Interest Purchase Agreement, dated as of March 16, 2017, by and among Caladrius, PCT, LLC, a Caladrius Company, a majority owned subsidiary of Caladrius (&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PCT</font><font style="font-family:inherit;font-size:10pt;">&#8221;), and Hitachi Chemical Co. America, Ltd. (&#8220;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Hitachi</font><font style="font-family:inherit;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Todd C. Girolamo, Esq. sent the following email on May 9, 2017 to certain Caladrius stockholders:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dear Stockholder:&#160; </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By now you should have received and had a chance to review the proxy materials that were sent to you regarding the Caladrius annual Stockholder Meeting that is scheduled to occur on May 16, 2017.&#160; If you have not yet read the proxy materials, you can find them at &#160;</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">https://www.sec.gov/Archives/edgar/data/320017/000157104917003364/t1700949-defm14a.htm</font><font style="font-family:inherit;font-size:10pt;">.&#160; One of the seven proposals (Proposal 2) to be considered at that meeting is the approval of the agreement whereby Caladrius Biosciences, Inc. ("Caladrius" or the &#8220;Company&#8221;) seeks to sell the remaining 80.1% of its subsidiary, PCT, LLC, a Caladrius Company, to the Hitachi Chemical Co. America, Ltd. for $75 million, subject to potential adjustments.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The vote to approve Proposal 2 requires a "FOR" vote from over 50% of the outstanding shares of Caladrius.&#160; A failure to vote, or an abstention, is counted as a vote "AGAINST" the Proposal.&#160; Management recommends that you vote "FOR" each of the seven proposals.&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">If Proposal 2 does not secure the necessary shareholder vote for approval, Caladrius will need to seek capital through other means, of which there can be no assurance that additional funding will be available.&#160; Such conditions would raise substantial doubt about the Company&#8217;s ability to continue as a going concern. As a result, it is EXTREMELY IMPORTANT that you vote your shares</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The easiest way to vote your shares is by calling&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">877-777-8133</font><font style="font-family:inherit;font-size:10pt;">.&#160; You will need to answer a few questions to identify yourself and then you can cast your votes immediately.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If you have any questions about the Stockholder Meeting, the proposals for consideration, the proxy materials or how to cast your vote, you can call me directly at Caladrius at 212-584-4178 for guidance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thank you for your support at this critical time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yours truly,</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Todd Girolamo</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate Secretary</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Additional Information About the Transaction and Where to Find it</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 11, 2017, Caladrius filed a&#160;definitive proxy&#160;statement on&#160;Schedule 14A&#160;(the &#8220;Proxy Statement&#8221;) with the Securities and Exchange Commission (&#8220;SEC&#8221;) in connection with, among other things, the proposed sale to Hitachi Chemical Co. America, Ltd. (&#8220;Purchaser&#8221;) of the 80.1% membership interest in PCT, LLC, a Caladrius Company, that Purchaser does not already own (the &#8220;Sale&#8221;).&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investors and stockholders of Caladrius are urged to read the Proxy Statement and the other relevant materials because they contain important information about Caladrius, the Sale proposal and the other proposals described in the Proxy Statement.</font><font style="font-family:inherit;font-size:10pt;">&#160;The Proxy Statement, and any other documents filed by Caladrius with the SEC, may be obtained free of charge at the SEC&#8217;s website at </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.sec.gov</font><font style="font-family:inherit;font-size:10pt;">. In addition, investors and stockholders may obtain free copies of the documents filed with the SEC by Caladrius by directing such requests to Caladrius Biosciences, Inc., 420 Lexington Avenue, Suite 350, New York, NY 10170, Attn: Jacquelyn Briggs or </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">jbriggs@caladrius.com</font><font style="font-family:inherit;font-size:10pt;">, Telephone: (646) 606-2221.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Participants in the Solicitation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caladrius and its directors and executive officers may, under SEC rules, be deemed to be participants in the solicitation of proxies from Caladrius&#8217; stockholders in connection with the Sale proposal and the other proposals contained in the Proxy Statement.&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Information regarding Caladrius&#8217; directors and executive officers is contained in the Proxy Statement. Additional information regarding the participants in the solicitation of proxies and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Proxy Statement</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Safe Harbor for Forward Looking Statements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This communication contains forward-looking statements within the meaning of Private Securities Litigation Reform Act of 1995, including forward-looking statements regarding the Sale, the possibility of obtaining stockholder or other approvals or consents for the Sale and Caladrius&#8217; future prospects. These statements are neither promises nor guarantees, but involve risks and uncertainties </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">that could cause actual events or results to differ materially from those set forth in the forward-looking statements, including, without limitation: risks and uncertainties relating to potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Sale; risks related to the failure to complete the Sale; unexpected costs, charges or expenses relating to or resulting from the Sale; restrictions contained in, and termination fees that may be payable pursuant to, the purchase agreement relating to the Sale; litigation or adverse judgments relating to the Sale; risks relating to the completion of the proposed Sale, including the risk that the required stockholder vote might not be obtained in a timely manner or at all, or other conditions to the completion of the Sale not being satisfied; any difficulties associated with requests or directions from governmental authorities resulting from their review of the Sale; any changes in general economic and/or industry-specific conditions; and other risks detailed in Caladrius&#8217; filings with the SEC, including those disclosed under &#8220;Item 1A. Risk Factors&#8221; in Caladrius&#8217; Annual Report on&#160;Form 10-K&#160;filed with the SEC on March 17, 2017 and in subsequent reports on&#160;Forms 10-Q&#160;and&#160;8-K&#160;and other filings made with the SEC. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this communication. Caladrius does not intend, and disclaims any obligation, to update or revise any forward-looking information contained in this communication or with respect to the matters described herein.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
